| http://www.w3.org/ns/prov#value | - In addition to our clinical and scientific progress, we remain actively engaged in discussions and diligence activities, with multiple companies regarding potential partnerships and collaborations on several fronts, including various clinical and preclinical programs in the regenerative medicine area, as well as our 5HT2c agonist portfolio for obesity and other disorders such as schizophrenia, whi
|
